32 unknown. 32 Phase 3, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 32 | Unknown 32 |
| Phase 2 | 12 | Unknown 12 |
Follow Retinal Degeneration: new trials by email Literature Review of Retinal Degeneration trials Research Report on Retinal Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients Faricimab - Age-Related Macular Degeneration, Diabetic Macular Edema | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 30 | 2024-03-01 | 2024-08-27 |
| Prospective triAl of Modified Treat-and-extend Regimens With BroLucizumab in pachychOroid Neovasculopathy Brolucizumab Injection [Beovu] - Age-Related Macular Degeneration, Pachychoroid Neovasculopathy | Phase 3 | Unknown | Yeungnam University College of Medicine | 36 | 2023-01-01 | 2023-01-05 |
| The Effect of Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigmentosa Subtenon injection of Wharton jelly derived mesenchymal stem cells, Subtenon injection of Wharton jelly derived mesenchymal stem cell exosomes, Placebo - Retinitis Pigmentosa | Phase 2 / Phase 3 | Unknown | TC Erciyes University | 135 | 2022-08-05 | 2022-09-07 |
| Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases Triamcinolone Acetonide - Central Serous Chorioretinopathy, Irvine-Gass Syndrome | Phase 2 / Phase 3 | Unknown | Benha University | 50 | 2022-04-14 | 2022-04-20 |
| Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis® GNR-067, Lucentis® - Age Related Macular Degeneration (ARMD) | Phase 3 | Unknown | AO GENERIUM | 408 | 2022-03-20 | 2023-09-13 |
| Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin bevacizumab with oral curcumin, bevacizumab with oral placebo - Diabetic Macular Edema, Macular Edema | Phase 2 / Phase 3 | Unknown | Isfahan University of Medical Sciences | 52 | 2021-10-10 | 2024-09-19 |
| An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. sepofarsen - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Unknown | ProQR Therapeutics | 15 | 2021-03-23 | 2022-03-25 |
| BEOVU Versus Eylea in the Treatment of Diabetic Macular Edema BEOVU intravitreal injection - Macular Edema | Phase 3 | Unknown | Benha University | 60 | 2021-01-12 | 2021-07-08 |
| A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD） LY09004, Eylea - Age Related Macular Degeneration | Phase 3 | Unknown | Luye Pharma Group Ltd. | 416 | 2020-11-01 | 2020-10-01 |
| Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial Combined Intravitreal bevacizumab and propranolol, Intravitreal bevacizumab - Age Related Macular Degeneration | Phase 2 / Phase 3 | Unknown | Shahid Beheshti University of Medical Sciences | 40 | 2018-09-01 | 2018-08-01 |
| Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD Squalamine lactate ophthalmic solution, 0.2%, Placebo Ophthalmic solution, ranibizumab - Age-related Macular Degeneration | Phase 3 | Unknown | Ohr Pharmaceutical Inc. | 230 | 2016-04-12 | 2017-04-27 |
| Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients Ranibizumab, Bevacizumab, Aflibercept - Age Related Macular Degeneration | Phase 2 / Phase 3 | Unknown | East Florida Eye Institute | 80 | 2014-12-01 | 2015-08-11 |
| Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO) Bevacizumab, Ranibizumab - Retinal Vein Occlusion | Phase 2 / Phase 3 | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 296 | 2012-06-01 | 2015-07-01 |
| Treatment Of Radiation Retinopathy Trial ranibizumab, triamcinolone acetonide, sham - Uveal Melanoma | Phase 2 / Phase 3 | Unknown | Leiden University Medical Center | 220 | 2009-09-01 | 2009-07-02 |
| Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration Ranibizumab (Intravitreal injection), Bevacizumab (Intravitreal injection) - Age Related Macular Degeneration | Phase 3 | Unknown | Instituto de Olhos de Goiania | 500 | 2009-03-01 | 2011-11-22 |
| Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO) Ranibizumab, macular laser photocoagulation - Branch Retinal Vein Occlusion | Phase 3 | Unknown | Seoul Retina Investigator Group | 60 | 2009-01-01 | 2010-08-26 |
| Subretinal Macugen® for Neovascular Age-Related Macular Degeneration Pegaptanib (Macugen®) - Age-related Macular Degeneration | Phase 3 | Unknown | Klinikum Ludwigshafen | 10 | 2008-11-01 | 2011-09-27 |
| Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab bevacizumab, ranibizumab - Age-Related Neovascular Macular Degeneration | Phase 3 | Unknown | Klinikum Bremen-Mitte, gGmbH | 366 | 2008-08-01 | 2009-03-26 |
| Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration Ranibizumab, Bevacizumab - Age Related Macular Degeneration | Phase 3 | Unknown | The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery | 320 | 2008-07-01 | 2010-06-09 |
| Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy ranibizumab - Age Related Macular Degeneration | Phase 3 | Unknown | The New York Eye & Ear Infirmary | 20 | 2007-06-01 | 2011-12-05 |
Showing 20 of 32. Sign in to see all of them.
Macular Degeneration (23) · Macular Edema (7) · Retinal Vein Occlusion (3) · Choroidal Neovascularization (2) · Diabetic Retinopathy (2) · Retinal Diseases (2) · Vision Disorders (2) · Blindness (1) · Cataract (1) · Central Serous Chorioretinopathy (1) · Choroid Diseases (1) · Eye Abnormalities (1) · Eye Diseases (1) · Histoplasmosis (1) · Leber Congenital Amaurosis (1)
Eye Diseases (31) · Retinal Diseases (30) · Macular Degeneration (7) · Cardiovascular Diseases (5) · Pathological Conditions, Signs and Symptoms (5) · Vascular Diseases (5) · Uveal Diseases (4) · Choroid Diseases (3) · Embolism and Thrombosis (3) · Metaplasia (3) · Neovascularization, Pathologic (3) · Pathologic Processes (3) · Thrombosis (3) · Venous Thrombosis (3)
Ranibizumab (11) · Bevacizumab (10) · Triamcinolone Acetonide (5) · Aspirin (2) · aflibercept (2) · beta Carotene (2) · Ascorbic Acid (1) · Control Groups (1) · Curcumin (1) · Exercise (1) · Glatiramer Acetate (1) · Intravitreal Injections (1) · Propranolol (1) · Triamcinolone (1) · Verteporfin (1)
Shahid Beheshti University of Medical Sciences (4) · National Eye Institute (NEI) (3) · Benha University (2) · AO GENERIUM (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Canadian Retinal Trials Group (1) · East Florida Eye Institute (1) · Instituto de Olhos de Goiania (1) · Isfahan Ophthalmology Research Center (1) · Isfahan University of Medical Sciences (1) · Kaplan Medical Center (1) · Klinikum Bremen-Mitte, gGmbH (1) · Klinikum Ludwigshafen (1) · Leiden University Medical Center (1) · Luye Pharma Group Ltd. (1)
Iran (5) · United States (5) · Germany (4) · Canada (3) · Austria (2) · Brazil (2) · Israel (2) · Netherlands (2) · United Kingdom (2) · Belgium (1) · Bulgaria (1) · China (1) · Czechia (1) · Egypt (1) · Ireland (1)
Hamid Ahmadieh, MD (3) · Ahmed A Abdelshafy, MD (1) · Avner Ingerman, MD (1) · Ayala Pollack, MD (1) · Bernd Muehlbauer, Professor MD (1) · David A Maberley, M.D. (1) · Irving Siegel, MD (1) · Jae Pil Shin, M.D. (1) · Jeffrey A Nau, MMS (1) · Lars-Olof Hattenbach, MD (1) · Martine J Jager, MD, PhD (1) · Oksana Markova, MD (1) · Panpan Ye, doctor (1)
PMID 17353403, PMID 17917738, PMID 19237716, PMID 19506188, PMID 19748675, PMID 23292928, PMID 32844399